title: [Effect of Naoshuantong capsule on change of SSQOL index in patients with ischemic stroke in six mouths follow-up].
abstract: To evaluate the effect of Naoshuantong capsule on the life quality of patients with ischemic stroke in six months of follow-up studies, and observe the adverse events. The results would provide reference for the secondary prevention on the recovery stage of ischemic stroke. 696 patients from 12 Class III Grade I hospitals nationwide were divided into 2 groups by central randomization system. The study group, 344 cases, were treated with Naoshuantong capsule plus Aspirin, and the control group, 352 cases, were treated with Aspirin. The patients were treated for 6 months. At the end of treatment, SS-QOL used for evaluating the quality of life was observed. The safety index was defined by adverse observation event. The incidence of adverse events and laboratory tests results were observed before and after treatment at the same time. The results indicated that compared to the control group, the treatment group had significant statistical difference in the impact of effort, self-care ability and the the work or labor ability of patients (P < 0.05). No serious adverse events were observed. Naoshuantong capsule showed some superiority to Asprin on improving the quality of life on patients with ischemic stroke, and it could be used in secondary prevention on the recovery stage of ischemic stroke. Naoshuantong capsule is safe and effective in the treatment of convalescence ischemic stroke.
authors.forename: Xiao-qin
authors.initials: XQ
authors.lastname: Ye
authors.forename: Yan-ming
authors.initials: YM
authors.lastname: Xie
authors.forename: Yi-huai
authors.initials: YH
authors.lastname: Zou
authors.forename: Xin-quan
authors.initials: XQ
authors.lastname: Zhao
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Han
authors.forename: Xin-zhi
authors.initials: XZ
authors.lastname: Wang
authors.forename: Yun-zhi
authors.initials: YZ
authors.lastname: Ma
authors.forename: Qi
authors.initials: Q
authors.lastname: Bi
authors.forename: Qin-fan
authors.initials: QF
authors.lastname: Xie
authors.forename: Jian-jun
authors.initials: JJ
authors.lastname: Zhao
authors.forename: Xiao-lan
authors.initials: XL
authors.lastname: Cao
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Chen
authors.lastname: Wang Shi-zhong
authors.forename: Yong-mei
authors.initials: YM
authors.lastname: Yan
authors.forename: Zu-cheng
authors.initials: ZC
authors.lastname: Han
authors.forename: Dan-hui
authors.initials: DH
authors.lastname: Yi
authors.forename: Yong-yan
authors.initials: YY
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D002214:Capsules / Q000008:administration & dosage / Q000009:adverse effects; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D020521:Stroke / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal